IP disputes in focus as TPP talks resume

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

IP disputes in focus as TPP talks resume

Negotiators in Europe might still be preparing for the next round of transatlantic trade negotiations from the beach but those from countries on the Pacific Rim are already getting ready for a resumption in talks this week

Friday sees the start of the latest (the 19th in fact) round of talks for the Trans-Pacific Partnership (TPP) in Bandar Seri Begawan, Brunei. The country will play host to sherpas – the negotiators that do the heavy lifting before a deal is agreed – from the US, Australia, New Zealand, Chile, Peru, Brunei, Singapore, Malaysia, Vietnam, Canada, Mexico and Japan.

IP is already proving one of the hardest topics to resolve. That’s not surprising, given the gulf in economic development between, say, Vietnam on the one side and the US on the other.

TPP negotiators

The US government is understood to be pushing its trading partners to accept a range of so-called TRIPs-plus measures on IP, including patent term extensions and tougher rules on data exclusivity. It’s not just about pharmaceutical patents either. Negotiations continue to beef up regional rules on well-known trade marks, relax rules on what constitutes a trade mark and to give copyright owners more rights over their works.

So far, so what? The talks are simply rehashing old arguments about the level of protection countries should offer IP owners that have gone on since trade negotiators added IP to the table in the 1990s.

But what makes these talks different is the lengths to which negotiators are going to be seen to be open to all stakeholders. ACTA negotiators were stung (and ultimately beaten) by protestors angry about deals being conducted in secret and parliamentarians cross about being asked to rubber stamp agreements over which they had no control. Now many of the deal makers are trying to improve levels of transparency in the talks.

Of course some of this is window dressing. In the September issue of Managing IP we take a closer look at free trade deals and what they mean for IP owners and hear from stakeholders on both sides of the pharmaceutical patent divide. It still appears that big pharma has more direct access to their national negotiators than do groups that are sceptical about the expansion of IP rights.

But negotiators are providing more opportunities than ever for stakeholders to get involved. At the 16th round of TPP talks, for example, negotiations were adjourned for a day for meetings with some of the 300 stakeholders who were able to make it to Singapore. In Brunei a morning has been set aside for stakeholder presentations.

Such moves might not be enough to end complaints about secrecy and the close relationship between governments and big business. But they might help governments conclude an agreement that is more palatable to their electorates. As ACTA demonstrated, a one-sided deal can mean no deal at all.

more from across site and SHARED ros bottom lb

More from across our site

VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Patent attorney Michael Henson joins the firm to lead its freshly launched blockchain and digital assets practice
A dispute over mammogram technology, and a development in the case between GSK and Moderna were also among the top talking points in recent weeks
With rankings for Western Europe set to be published on June 25, we sat down with our research lead to find out what practitioners and law firms can expect
Peter O’Sullivan, a professional services executive, says he is looking forward to helping Pearce IP become the leading life sciences firm in Australia and New Zealand
Matteo Di Lernia, advocate at LCA Studio Legale, unpicks the CJEU’s ruling in M.M. Ristorazione v Villa Ramazzini, including its impact on litigation strategies
Gift this article